Second-Line Treatment Landscape for Advanced HCC

 

ASCO 2022 Conference Coverage
A

Lecture Summary - ASCO 2022 on an Open-Label, Multicenter, Randomized Phase II Study of Atezolizumab & Bevacizumab With Y90 TARE in Unresectable HCC

By ASCO 2022 Conference Coverage FEATURING Aiwu Ruth He, Filip Banovac
By ASCO 2022 Conference Coverage FEATURING Aiwu Ruth He, Filip Banovac
8 views
June 23, 2022
0 Comments
Login to view comments. Click here to Login
Second-Line Treatment Landscape for Advanced HCC
17:15
Lorenza Rimassa

2L Systemic Treatment Approaches for Advanced HCC

15:29
10th Annual Winship Cancer Institute Gastrointestinal Cancer Virtual Symposium

Sequencing Therapy in Hepatocellular Carcinoma: A Good Problem to Ha…

Feat. M. Akce
13:03
CECOG Academy

Updates on Cabozantinib in RCC, HCC, and Thyroid Cancers

Feat. B. Mrinakova
24:13
UChicago Medicine: Sixth Annual Updates in Digestive Diseases

Liver Transplantation for HCC: Role of AFP, Overview of Current &…

Feat. A. A. Pillai
33:00
35th Annual New Treatments in Chronic Liver Disease

Systemic Therapies for HCC: What Does the Gastroenterologist Need to…

Feat. C. Frenette, J. Gutierrez, C. J. Karvellas
07:19
Northwell Health

Cabozantinib in Patients With Advanced and Progressing Hepatocellula…

Feat. A. Levy
31:02
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2022

Updates in Systemic Therapy for HCC

Feat. R. Finn
55:46
University of Colorado Cancer Center

UColorado Updates on Hepatocellular Carcinoma and Biliary Tract Canc…

Feat. L. Davis
09:02
ASCO 2022 Conference Coverage

ASCO 2022 Immunotherapy With Nivolumab After Progression on Lenvatin…

Feat. A. Rauthan
05:12
ASCO 2022 Conference Coverage

ASCO 2022 IMMUNIB Trial: A Single-Arm, Phase II Study Evaluating Saf…

Feat. A. Vogel
39
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Immunotherapy With Nivolumab After Progr…

Feat. A. Rauthan
04:54
ASCO 2022 Conference Coverage

ASCO 2022 IMMUTACE - A Biomarker-Orientated Phase II, Single-Arm, Op…

Feat. A. Vogel
07:35
ASCO 2022 Conference Coverage

ASCO 2022 on an Open-Label, Multicenter, Randomized Phase II Study o…

Feat. A. Ruth He, F. Banovac
40
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on an Open-Label, Multicenter, Randomize…

Feat. A. Ruth He, F. Banovac
05:07
Icahn School of Medicine at Mount Sinai

TKI in the Management of Advanced HCC

Feat. A. Villanueva
03:33
ASCO 2022 Conference Coverage

ASCO 2022 Patient-Reported Outcomes From the Phase 3 HIMALAYA Study …

Feat. P. Galle
10:11
ASCO 2022 Conference Coverage

ASCO 2022 on Atezolizumab + Bevacizumab vs Lenvatinib or Sorafenib i…

Feat. M. Rimini